^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prostate Cancer
    Drug:Camcevi 42 mg (leuprolide 6-month depot) (GnRH agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Foresee Pharmaceuticals Press Release
    Title:

    Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord Healthcare to Head the E.U. Commercialization

    Published date:
    05/31/2022
    Excerpt:
    Foresee Pharmaceuticals...announced today that the European Commission (EC) has approved the Marketing Authorization Application (MAA) for CAMCEVI® 42 mg prolonged-release suspension for injection, for the treatment of hormone-dependent advanced prostate cancer and for the treatment of high-risk localized prostate cancer and locally advanced hormone-dependent prostate cancer in combination with radiotherapy. The approval is applicable to all 27 European Union (EU) Member States, Iceland, Norway and Liechtenstein
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.